Drug development in Alzheimer’s disease: the contribution of PET and SPECT

Drug development in Alzheimer’s disease: the contribution of PET and SPECT

Clinical trials aiming to develop disease-altering drugs for Alzheimer’s disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion- and outcome criteria, due to a limited amount of objective biomarkers, is one of the major con...

Full description

Bibliographic Details
Main Authors: Lieven Denis Herwig Declercq, Rik eVandenberghe, Koen eVan Laere, Alfons eVerbruggen, Guy eBormans
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-03-01
Series:Frontiers in Pharmacology
Subjects:
PET
biomarkers
Alzheimer’s disease
Drug Development
SPECT
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00088/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00088/full

Similar Items